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1. Introduction
Gastritis, the inflammation of the mucosal layer of the stomach, is a major clinical entity due
to its association with gastric cancer and peptic ulcer disease. The primary cause of gastritis
is the infection with the microaerofilic gram negative Helicobacter pylori that during the
early phases elicits an acute inflammatory response which eventually evolves to a long-
standing chronic gastritis (Ruggiero 2012). In the case of gastric cancer development, chronic
gastritis is the first step of the so-called multistep cascade of gastric cancer. This sequence
includes the non-atrophic chronic gastritis, multifocal atrophic gastritis, intestinal metapla‐
sia, dysplasia and invasive carcinoma as were described in detail by Correa as the “human
model of gastric carcinogenesis” (Fig. 1) (Correa et al. 2007). This multistep model hypothe‐
sizes that the sequence of these lesions reflects a dynamic process from a naive inflammation
caused by H. pylori infection to a fully malignant neoplasm of the stomach (Correa et al.
1976; Cuello et al. 1976; Haenszel et al. 1976; Correa et al. 1990). Independent epidemiologi‐
cal studies have confirmed that non-atrophic, atrophic, intestinal metaplasia and dysplasia
are all linked through a sequential cause-effect relationship, thus supporting the concept of a
human model for gastric carcinogenesis (Ohata et al. 2004). However, the risk of malignant
transformation of these lesions is poorly defined. Long-term follow-up studies have shown
a risk from 10% to 17% in the case of dysplasia (Saraga et al. 1987; Coma del Corral et al.
1990; Koch et al. 1990; Whiting et al. 2002; Rugge et al. 2003). For intestinal metaplasia, the
risk assessment has conflicting results and therefore a limited clinical value (Ramesar et al.
1987; Silva et al. 1990; Rokkas et al. 1991; Conchillo et al. 2001; Vannella et al. 2012). The re‐
cently developed Operative Link for Gastritis Assessment (OLGA) staging system (Rugge et
al. 2007), through the evaluation of the extension and site of the atrophic changes, is an at‐
tempt to evaluate the risk of chronic gastritis to progress to intestinal metaplasia and gastric
cancer (Rugge et al. 2008; Capelle et al. 2010; Rugge et al. 2010). In this scenario, the identifi‐
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cation of molecular bases in the multistep process of gastric carcinogenesis is highly relevant
since it will contribute greatly to the risk assessments of the precursor lesions of gastric can‐
cer. In this chapter we will primarily attempt to summarize and integrate our current
knowledge of the genetic as well as epigenetic bases of the dynamic process of chronic gas‐
tritis, as well as the other entities of the so-called multistep cascade of gastric cancer.
Figure 1. Multistep cascade of gastric cancer. This sequence begins with the infection of H.pylori to sequential steps of
the precancerous cascades. Taken from Correa & Piazuelo J Dig Dis. 2012;13:2–9.
2. The genetic bases of gastritis
Human allelic variations at single nucleotide polymorphisms (SNP) are involved at different
stages of gastric carcinogenesis. Accordingly, the dynamics of chronic gastritis might be as‐
sociated with specific allelic variants. These variants, recognized as polymorphisms when
occur with a frequency of >1% in the normal population, affects mostly genes of the inflam‐
matory response genes, detoxification enzymes, and cancer-related procesess (Gonzalez et
al. 2002).
Polymorphisms in inflammatory response genes
Two clear examples of polymorphisms associated with inflammatory response are interleu‐
kin-1 gene cluster and Toll-like receptors (TLRs). As shown in Table 1, Interleukin-1-beta
(IL-1B) -31 T genotype and interleukin-1-receptor antagonist (IL1RN) IVS 86 bp VNTR, 2/2
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genotype enhance the production of IL-1B, which is associated with an increased risk of hy‐
pochlorhydria induced by H. pylori. Because IL-1B is an important pro-inflammatory cyto‐
kine and a powerful inhibitor of gastric acid secretion, it might explain the higher risk of
development of gastric cancer in chronic gastritis - H. pylori infected patients (El-Omar et al.
2000; Hwang et al. 2002; Yuzhalin 2011). The presence of polymorphisms in the non-coding
but regulatory regions may also alter the levels of gene transcription and therefore the sus‐
ceptibility to gastric cancer. In this sense, single A/T SNP at position -251 from the transcrip‐
tion start site in the promoter region of the IL-8 gene is one of the best examples. The
presence of the -251A allele tended to be associated with an increase in IL-8 production and
has been reported that this allele is associated with an increased risk for gastric cancer at car‐
dia location (Hull et al. 2000; Xue et al. 2012). It could be extrapolated that IL-8 -251A allele
may increase the risk of developing cancer through the elevation of its IL-8 expression. Me‐
diators of the innate immune response, which provide first line of host defense against
harmful pathogens are also involved in the dynamics of chronic gastritis. A good example
for this type of inflammatory response are the Toll-like receptors (TLRs) (El-Omar et al.
2008). It has been reported that both, the 22-bp nucleotide deletion (-196 to –174 del) in the
promoter region of the TLR-2 gene and the +896A/G and +1196C/T polymorphisms
(Asp299Gly and Thr399Ile) in the coding region of the TLR-4 gene, promotes a rapidly pro‐
gressive chronic gastritis (de Oliveira et al. 2012). Since it is well known that not all H. pylori
are equally associated with the risk of development of gastric cancer, the combination of
bacterial and inflammatory host genotypes have been explored. Figueiredo et al (2002) have
shown that the infection with aggressive cagA-positive strains of H. pylori were associated
with an increased risk of gastric cancer. In addition, the homozygous IL-1B-511*T carriers
(IL-1B-511*T/*T or IL-1B-511*T/*C) and the short allele of IL-1RN (IL-1RN*2/*2) also had an
increased susceptibility. However, for each combination of bacterial/host genotype, the odds
of having gastric cancer were greatest in those with both bacterial and host high-risk geno‐
types.
Polymorphisms in genes associated with detoxification enzymes
Members of the cytochrome P-450 superfamily belong to the detoxification enzymes. One of
the members of this family is the CYP2E1, a naturally ethanol-inducible enzyme involved in
the metabolic activation of low molecular weight compounds such as N-nitrosamines (Boc‐
cia et al. 2007). Functional CYP2E1 polymorphisms in the 50-flanking region (PstI, RsaI) alter
the transcriptional activity of the gene. A meta-analysis by Boccia et al (2007) suggests that
the CYP2E1 PstI/RsaI polymorphism may be a risk factor for gastric cancer in asiatic popula‐
tions and a synergic relation with tobacco-related detoxification Glutathione S-transferase
(GST) genes (see below) may account for a proportion of these cases. GSTs and the polymor‐
phic arylamine N-acetyltransferases (NAT1 and NAT2) are another type of detoxification
enzymes that metabolize tobacco-related carcinogens. Zendehdel et al (2009) reported a
weak linkage between the GSTP1 Ile105Val polymorphism and the risk for gastric cancer at
cardia location (OR = 1.4; 95% CI 0.9-2.1). On the other hand, Katoh et al (2000) found that
the NAT1*10 allele should be considered a risk factor among heavy smokers with well-dif‐
ferentiated tumors (Table 1).
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Polymorphisms of cancer-related genes
In cancer-related processes, polymorphisms have been reported in the promoter region of
the MET gene, a crucial gene to multiple oncogenic pathways and metastatic behavior
(Gherardi et al. 2012). Sequencing of the promoter region of MET revealed some alterations
scattered in a proportion of clinical samples of gastric cancer. The most common substitu‐
tions were -304C>A and 206C>G. The presence of these SNPs altered the junction sites for
putative transcription factors such as Sp1 and AP-1/AP-2. As a consequence, the transcrip‐
tion of MET was constantly being activated (Trzyna et al. 2012). Another example is the
polymorphism -160 A at the promoter region of the E-cadherin gene (CDH1), which has
been associated with the DNA hypermethylation (see below) of the promoter region (Borges
Bdo et al. 2010). In a Japanase study, 117 cases of gastric cancer with H. pylori-induced
chronic gastritis were compared with 116 cancer-free yet H. pylori-induced chronic gastritis
controls. It was found that the Pro/Pro allele of CDH-1 was associated with an increased risk
of developing diffuse-type of gastric cancer compared to the Arg/Arg (Hiyama et al. 2002;
Zhou et al. 2007). Finally, other polymorphims of cancer-related genes were reported to
show significant associations with gastric cancer risk including EGFR, VEGF and p53 (Ta‐
hara et al. 2009). Taken together, data presented here suggest that allelic variations at regula‐
tory or coding regions will affect gene expression patterns and modify the balance towards a
more rapid progression of chronic gastritis and other preneoplastic lesions of the multistep
cascade of gastric cancer (Fig. 2).
Figure 2. Allelic variations at regulatory regions will affect gene expression patterns. (A) Single nucleotide polymor‐
phisms (SNP) in promoter region can alter the binding of transcription factors required for the expression of a gene.
(B) These variations may increase or decrease the expression of the affected gene, which eventually can increase the
risk of developing cancer.
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Gene Variation Allelic SNP rs number Effect Reference
IL1B SNP -31 T/C rs1143627 Increased IL-1beta productionand inhibit gastric acid secretion.
(Yuzhalin et
al., 2011)
IL-8 SNP -251 A/T rs4073 Increased IL-8 production. (Xue et al.,2012)
IL-10 SNP -1082 A/G rs1800896
Reported associated with the
pathologically intestinal-type
gastric cancer or anatomically
cardia-type gastric cancer.
(Ni et al.,
2012)
TLR2 Deletion -196 to -174del not applicable Susceptibility to gastric cancer in
the Southeastern Brazilian
population.
(de Oliveira et
al, 2012)TLR4 SNP + 896 A/G rs4986790
CYP2E1 RFLP CYP2E1 c2 allelehomozygote not applicable
Risk for gastric cancer among
Asians
(Boccia et al.,
2006)
GSTP1 SNP +562 A/G rs1695
Increased risk of esophageal
squamous cell carcinoma and
tended to be weakly, positively
linked to cardia cancer
(Zendehdel et
al., 2009)
NAT RFLP NAT1*10 allele not applicable
Risk factor among the well-
differentiated type of tumors of
gastric cancer
(Katoh et al.,
2000)
MET SNP -304C> A undefined Activate the transcription. (Trzyna et al.,2012)SNP 206 C>G undefined
CDH1 SNP -160 C/A rs16260
Associated with DNA methylation
linking genetic and epigenetics
fields in the pathogenesis of
gastritis.
(Borges Bdo
et al., 2010)
Table 1. Selected single nucleotide polymorphisms (SNP) in inflammatory response genes, detoxification enzymes,
and cancer-related processes associated to increase susceptibility of gastric cancer. The sign (-) indicates that the SNP
is located in the direction of the promoter region, the sign (+) indicates that the SNP is located in the direction of the
coding region, the number indicates the nucleotide positionfrom TSS and the first nucleotide is substituted (/) by the
second.
3. Epigenetic bases of gastritis
Epigenetic processes control the packaging and function of the human genome, and contrib‐
ute to normal development and disease (Callinan et al. 2006). Epigenetic mechanisms such
as DNA methylation, histone modifications and microRNAs are important events toward
regulating gene expression for the biology and disease of the gastrointestinal tract. In partic‐
ular, DNA methylation, a process in which cytosines acquire a methyl group in the 5' posi‐
tion only if they are followed by a guanine (Corvalán et al. 2010), virtually affects all of the
pathways in the cellular network, such as DNA repair, cell cycle, and apoptosis (Esteller et
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al. 2002). Furthermore, a growing body of evidence has shown that aberrant DNA methyla‐
tion (DNA hypermethylation or DNA hypomethlation) is an early event in carcinogenesis
(Jones et al. 2002; Herman et al. 2003; Kopelovich et al. 2003). In addition, aberrant DNA
methylation has been recently considered to be an excellent candidate to explain how cer‐
tain environmental factors may increase the risk of developing cancer (Chan et al. 2006). Ac‐
cordingly, an emerging catalog of cancer-related genes inactivated by DNA
hypermethylation in gastric cancer has been established (Hamilton et al. 2006; Wu et al.
2006; Bernal et al. 2008). However, there are limited reports on DNA hypermethylation anal‐
ysis in precursor lesions of gastric cancer. Kang et al. (2001) tested five genes (p16, hMLH1,
DAP-kinase, THBS1, and TIMP-3) in precancerous conditions to identify three different
classes of hypermethylated genes. Hypermethylation of DAP-kinase was found in all pre‐
malignant conditions, whereas hMLH1 and p16 were preferentially methylated in intestinal
metaplasia (6.3% and 2.1%, respectively), adenomas (9.8% and 11.5%, respectively) and gas‐
tric cancer (20.3% and 42.2%, respectively). THBS-1 and TIMP-3 were also hypermethylated
at a similar frequency in all premalignant conditions, but showed a marked increase from
chronic gastritis to intestinal metaplasia (10.1% & 34.7% and 14.5% & 36.7%, respectively; P
< 0.05), as well as from adenomas to carcinomas (28.3% & 48.4% and 26.7% & 57.4% respec‐
tively). Another study including 11 genes (COX-2, DAP-kinase, E-cadherin, GSTP1, MGMT,
hMLH1, p14, p16, THBS1, TIMP3, and RASSF1A) and 268 premalignant conditions (Kang et
al. 2003) identified specific patterns of aberrant DNA methylation associated to aging. Spe‐
cifically five genes (DAP-kinase, E-cadherin, p14, THBS1, and TIMP-3) showed a progres‐
sive increase in aberrant methylation frequency as a function of aging, whereas the other
genes (COX-2, GSTP1, MGMT, hMLH1, p16, and RASSF1A) were rarely methylated. Male
patients showed higher numbers of hypermethylated genes than females (3.2 vs. 2.1, respec‐
tively, P = 0.002) and cases with severe intestinal metaplasia also showed a higher frequency
of aberrantly methylated genes. Taken together, these findings suggest that hypermethyla‐
tion occurs early in the multistep gastric carcinogenesis and that accumulate during this
process. In addition, age and gender are closely associated with increased frequency of aber‐
rant DNA methylation. A further study demonstrated that DNA methylation of E-cadherin
was associated with H. pylori infection (p=0.002) in an independent way of age and/or gas‐
tritis (Chan et al. 2003). Similarly, Maekita et al. (2006) carried out a more detailed analysis
of the effect of H. pylori infection in the progression of aberrant DNA methylation in chronic
gastritis. These authors collected gastric mucosa samples from 154 healthy volunteers (56 H.
pylori negative and 98 H. pylori positive) and from 72 cases with gastric cancers (29 H. pylo‐
ri negative and 43 H. pylori positive). Among the healthy volunteers, methylation levels
were 5.4- to 303-fold higher in H. pylori positive subjects than in H. pylori negative ones (P <
0.0001). Particularly, methylation levels of the LOX, HAND1 and THBD at their promoter
regions were identified in H. pylori-positive individuals. Among H. pylori-negative individ‐
uals, methylation levels were 2.2- to 32-fold higher in gastric cancer cases than in age-match‐
ed healthy volunteers. These findings suggest that H. pylori infection potently induces
aberrant DNA methylation of several genes beyond E-cadherin, and that methylation levels
of specific genes seemed to reflect the risk of gastric cancer in H. pylori-negative subjects. A
recent quantitative analysis of the promoter region of a novel gene Reprimo (RPRM), per‐
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formed in Colombian residents from areas with high and low incidence of gastric cancer,
demonstrated an association with virulent factors such as cagA and vacA s1/m1 regions of
H. pylori strains. This data suggests that certain strains of H. pylori are associated with aber‐
rant DNA methylation on specific genes (Schneider et al. 2010). Interestingly, we have
shown that Reprimo is not only found in gastric mucosa but also in the plasma of gastric
cancer patients (Bernal et al. 2008). Thus, hypermethylated circulating DNA offers the op‐
portunity for non-invasive detection of gastric cancer and premalignant gastritis (Corvalán
et al. 2010; Sapari et al. 2012). As mentioned before, an aberrant of DNA methylation could
be considered as a candidate to explain how environmental factors increase the susceptibili‐
ty of gastric cancer. One approach to explain this phenomena could be through the evalua‐
tion of the effect of the eradication of H. pylori in the pattern of DNA methylation of the
gastric mucosa. Chen et al (2003) evaluate the presence of DNA methylation of E-cadherin
promoter regions before the erradication of H. pylori and after 6 weeks of treatment. DNA
methylation of E-cadherin was detected in 46% (19/41) and 17% (7/41) of both untreated and
treated patients, respectively. Mucosal biopsy showed chronic inactive gastritis in 35 pa‐
tients, intestinal metaplasia in one patient and normal mucosa in five patients after the treat‐
ment. This data suggests that H. pylori eradication therapy could reverse aberrant DNA
methylation in patients with chronic gastritis. Similar results were reported by Leung et al.
(2006), although they evaluated mucosal biopsies from the antrum and corpus of H. pylori-
infected subjects at the baseline, and after one year of successful H. pylori eradication. In ad‐
dition, these authors identified a significant reduction in the methylated density of the
promoter region of the E-cadherin gene (Leung et al. 2006). Taken together, both reports are
clear examples of how the environment affects DNA methylation and shows that the eradi‐
cation of H. pylori infection reverses E-cadherin promoter hypermethylation. Although less
explored, DNA hypomethylation can also be involved in the risk of developing cancer. The
concept of DNA hypomethylation, although identified 30 years ago (Christman et al. 1977),
was overlooked in preference to DNA hypermethylation. Recently, gene activation by pro‐
moter hypomethylation has been rediscovered (Ichinose et al. 1988; Cravo et al. 1996; Fang
et al. 1996; Akiyama et al. 2003; Cho et al. 2003; Mesquita et al. 2003; Oshimo et al. 2003;
Chalitchagorn et al. 2004; Honda et al. 2004; Kaneda et al. 2004; Yanagawa et al. 2004; Jung et
al. 2005; Nishigaki et al. 2005). Emerging data suggests that global DNA hypomethylation is
thought to occur during the early stages of gastric carcinogenesis (Goelz et al. 1985; Cravo et
al. 1996; Narayan et al. 1998; Lin et al. 2001; Bariol et al. 2003) but hypomethylation of indi‐
vidual genes, such as MAGE, synuclein-alpha, MUC2, maspin, CAGE and family A melano‐
ma antigen (Akiyama et al. 2003; Cho et al. 2003; Mesquita et al. 2003; Honda et al. 2004;
Yanagawa et al. 2004; Jung et al. 2005) is thought to occur during the advanced stages. Inter‐
estingly, overexpression of well known oncogenes, such as MYC, HRAS1 and cyclin D2 has
been linked to hypomethylation in their promoter region, suggesting an inverse correlation
between methylation and gene expression (Fang et al. 1996; Oshimo et al. 2003). Taken to‐
gether, this data suggests that promoter hypomethylation is an underlying mechanism of
gene activation that should be explored in gastric carcinogenesis. In these sense, recent work
from Daskalos et al (2011) has shown that the overexpression of p73, a well stablish cancer-
related gene associated with apoptosis and DNA repair (Zaika et al. 2011), might be associ‐
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ated with hypomethylation of the P2 promoter region that controls the DeltaNup73 isoform.
Although this work was not performed in a gastric cancer model, our preliminary findings
suggests similar results in gastric cancer cases (Corvalán et al. 2008). Based on both data, we
decide to analysed the protein overexpression of p73 as well as other seven well stablished
cancer-related genes activated by hypomethylation (BRCA1, HSP90, STAT1, FHIT, EGFR,
p73, p53, p16INK4a) (Tanaka et al. 1998; Nien et al. 2007; Shutoh et al. 2009; Yu et al. 2009;
Valdez et al. 2010; Daskalos et al. 2011; Rusiecki et al. 2011; Szaumkessel et al. 2011; Fornari
et al. 2012). This analysis was performed in a large number of matched tumor/non-tumor
adjacent mucosa of early gastric cancer as well as non-tumor cases at different stages of the
multistep cascade of gastric cancer (Carrasco et al. 2010). Among 8 genes tested, only the
overexpression of p73 was higher in matched tumor/non-tumor adjacent mucosa than in
chronic gastritis/intestinal metaplasia (50.5% vs. 10.8%; P < 0.0001). We also assessed a detail
histopathological analysis of the precursor lessions of gastric cancer through the Sydney and
OLGA systems (Dixon et al. 1996; Corvalan et al. 2011; Rugge et al. 2011). As has been de‐
scribed (Rugge et al. 2010) only severe atrophy and OLGA stage IV were the most relevant
features to identified high-risk gastritis (Fig. 4). However, the most interesting finding come
after our attempt to integrated protein expression and histopathological assessments. This
integration was performed by Significance Analysis of Microarrays (SAM), a multiple test‐
ing approach method that has been extensively applied in genomic research (Tusher et al.
2001) and confirmed by logistic regression (Nick et al. 2007). This integrative approach led
us to identified that overexpression of p73 was even more significant than severe atrophy
and OLGA stage IV in identifying high-risk premalignant gastritis (Carrasco et al. 2010).
Therefore, we believe that the identification of the overexpression of p73 might contribute
greatly to risk assessment of chronic gastritis to the development of gastric cancer.
Figure 3. The effect of the eradication of H. pylori in the pattern of DNA methylation as an example of environmental
factors and the susceptibility of gastric cancer. (A) Before eradication of H. pylori (week 0), methylation was present in
patients 3, 5 and 6. (B) Bisulfite sequencing confirm the methylated product. (C) After eradication of H. pylori (week 6),
methylation was not present in any patient. (D) Bisulfite sequencing confirm the absence of methylated cytosine. MW:
molecular weight marker, U: unmethylated band, M: methylated band, red color: unmethylated cytosines converted
to thymidine, blue color: methylated cytosines. Taken from Chan et al., Gut 2006;55:463-8 with permission from BMJ
Publishing Group Ltd.
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Figure 4. Serial Analysis for Microarray from Non-tumor adjacent mucosa (NTAM) and chronic gastritis controls.
NTAM group is significantly characterized by the overexpression of p73, OLGA stages III to IV, and severe atrophy
(ATR-3), intestinal metaplasia (IM-3), and chronic inflammation (CI-3) according to the Sydney System. Control group
cases were significantly characterized by lack of intestinal metaplasia (IM-0), atrophy (ATR-0), and chronic inflamma‐
tion (CI-0). False discovery rate = 0. Taken from Carrasco et al., Clin.Cancer Res 2010;16:3253-9.
4. Conclusion
Data presented here suggests that genetic, epigenetic by means of DNA methylation might
play a role in the dinamics of the progression of chronic gastritis and premalignant cascade
to gastric cancer. DNA methylation works in both ways, inactivating or activating tumor-
related genes through the hypermethylation or hypomethylation of the promoter regions of
specific genes. The integration of these molecular bases of chronic gastritis with histolopa‐
thological assessment by Sydney and OLGA systems will contribute to the better risk assess‐
ment for the development of gastric cancer.
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